Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-09-13 pm EDT			5-day change	1st Jan Change
46.36 ^USD	+1.73%		+4.23%	+3.54%

Sep. 13	Qiagen, Bio-Manguinhos/Fiocruz Launch Malaria Detection Test in Brazil	MT
Sep. 12	Qiagen Expands Partnership with Bio-Manguinhos/Fiocruz for Malaria Screening	MT

QIAGEN NV : UBS reiterates its Neutral rating

August 02, 2024 at 05:18 am EDT

In a research note, UBS analyst Dan Leonard has maintained his recommendation on the stock with a Neutral rating.

Latest news about Qiagen N.V.

Qiagen, Bio-Manguinhos/Fiocruz Launch Malaria Detection Test in Brazil	Sep. 13	MT
Qiagen Expands Partnership with Bio-Manguinhos/Fiocruz for Malaria Screening	Sep. 12	MT
QIAGEN N.V. and Bio-Manguinhos/Fiocruz Collaborate to Enhance Malaria and Dengue Detection in Brazil's National Screening Programs	Sep. 12	CI
QIAGEN NV : Berenberg reaffirms its Buy rating	Sep. 11	ZD
Centogene N.V. Announces Supervisory Board Resignations	Sep. 06	CI
Transcript : Qiagen N.V. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-06-2024 09:15 AM	Sep. 06
Eli Lilly: agreements signed with Qiagen and Genetic Leap	Sep. 05	CF
Such a long wait	Sep. 05
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday	Sep. 05	MT
Qiagen Partners with Eli Lilly to Develop Testing Panel for Alzheimer's Disease	Sep. 05	MT
Qiagen, Eli Lilly Collaborate on APOE Genotype Test for Alzheimer's Diagnosis	Sep. 04	MT
Qiagen N.V. Enters into A Collaboration with Eli Lilly and Company to Support the Development of A QIAstat-Dx In-Vitro Diagnostic to Detect APOE Genotypes Which Can Play A Role in the Diagnosis of Alzheimer?S Disease	Sep. 04	CI
Transcript : Qiagen N.V. Presents at 21st Annual Goldman Sachs European Medtech and Healthcare Conference, Sep-04-2024 09:00 AM	Sep. 04
Qiagen Places $500 Million of Convertible Bonds	Sep. 04	MT
Qiagen to Issue $450 Million of Convertible Bonds due 2031	Sep. 03	MT
Qiagen Expands Companion Diagnostics Collaboration with AstraZeneca	Aug. 29	MT
Qiagen Expands Master Collaboration Agreement with AstraZeneca	Aug. 28	MT
Berenberg Lifts Price Target on Qiagen to EUR54.90 From EUR54.20, Keeps Buy Rating	Aug. 07	MT
QIAGEN NV : Berenberg maintains a Buy rating	Aug. 07	ZD
UBS Adjusts Price Target on Qiagen to $50 From $46, Maintains Neutral Rating	Aug. 02	MT
QIAGEN NV : UBS reiterates its Neutral rating	Aug. 02	ZD
Transcript : Qiagen N.V., Q2 2024 Earnings Call, Aug 01, 2024	Aug. 01
QIAGEN : Healthy Q2; profitability guidance upgraded	Aug. 01
QIAGEN NV : Berenberg gives a Buy rating	Aug. 01	ZD
QIAGEN NV : Receives a Buy rating from Goldman Sachs	Aug. 01	ZD

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,900

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - BofA Conference

More about the company